10.23
전일 마감가:
$9.61
열려 있는:
$9.6
하루 거래량:
73,199
Relative Volume:
0.05
시가총액:
$91.99M
수익:
$23.14M
순이익/손실:
$-9.47M
주가수익비율:
-11.59
EPS:
-0.8827
순현금흐름:
$-25.88M
1주 성능:
+9.52%
1개월 성능:
+107.41%
6개월 성능:
-30.35%
1년 성능:
+38.18%
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ATRA
Atara Biotherapeutics Inc
|
10.21 | 86.59M | 23.14M | -9.47M | -25.88M | -0.8827 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.19 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
630.88 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
823.05 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
294.80 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
152.44 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Atara Biotherapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - New Castle News
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - Mid Florida Newspapers
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Atara Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - The Globe and Mail
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - PR Newswire
Atara Biotherapeutics CAO sells $22,036 of company stock By Investing.com - Investing.com Canada
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock By Investing.com - Investing.com South Africa
Atara Biotherapeutics CEO AnhCo Nguyen sells $47,844 in stock - Investing.com
Atara (ATRA) CEO sells 5,241 shares in automatic tax sale - Stock Titan
Atara Biotherapeutics (ATRA) CAO sells 2,414 shares to cover RSU tax - Stock Titan
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. ... - Caledonian Record
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages - GlobeNewswire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara Biotherapeutics Raised to Hold From Sell by Freedom Broker - Moomoo
Atara Biotherapeutics Price Target Raised to $10.00/Share From $4.00 by Freedom Broker - Moomoo
ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Class Action Litigation Filed by Pomerantz LLP for Investors of Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ATRA Upgraded by Freedom Broker -- Price Target Raised to $10 - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - lincolnjournal.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATARA DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
[144] Atara Biotherapeutics, Inc. SEC Filing - Stock Titan
Company (NASDAQ: ATRA) RSU Settlement and 2,104-Share Sale - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Freedom Broker upgrades Atara Biotherapeutics stock rating on FDA meeting progress - Investing.com
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ... - Caledonian Record
Class Action Litigation Filed by Pomerantz LLP Concerning Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
Trading Systems Reacting to (ATRA) Volatility - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026ATRA - The Daily Tribune News
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아타라 주식 (ATRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
May 18 '26 |
Sale |
9.13 |
2,414 |
22,036 |
49,636 |
자본화:
|
볼륨(24시간):